Schwab Charles Investment Management Inc. Acquires 31,500 Shares of Fate Therapeutics Inc (FATE)

Schwab Charles Investment Management Inc. raised its holdings in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 47.7% in the first quarter, HoldingsChannel reports. The firm owned 97,500 shares of the biopharmaceutical company’s stock after buying an additional 31,500 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Fate Therapeutics were worth $952,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Rhumbline Advisers increased its stake in Fate Therapeutics by 32.7% during the 1st quarter. Rhumbline Advisers now owns 44,386 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 10,946 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 12,686 shares in the last quarter. Algert Global LLC bought a new stake in Fate Therapeutics during the 1st quarter valued at $172,000. Trexquant Investment LP bought a new stake in Fate Therapeutics during the 1st quarter valued at $179,000. Finally, Raymond James & Associates bought a new stake in Fate Therapeutics during the 4th quarter valued at $141,000. Institutional investors and hedge funds own 74.56% of the company’s stock.

A number of analysts have commented on FATE shares. ValuEngine upgraded shares of Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. BidaskClub lowered shares of Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. HC Wainwright reiterated a “hold” rating and issued a $12.00 target price on shares of Fate Therapeutics in a research note on Tuesday, March 20th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $19.00 target price on shares of Fate Therapeutics in a research note on Thursday, March 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $15.00.

Fate Therapeutics opened at $12.44 on Friday, according to MarketBeat.com. Fate Therapeutics Inc has a 1 year low of $2.52 and a 1 year high of $14.45. The company has a current ratio of 7.20, a quick ratio of 7.20 and a debt-to-equity ratio of 0.22.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.05). Fate Therapeutics had a negative return on equity of 77.27% and a negative net margin of 1,143.99%. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $1.82 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts predict that Fate Therapeutics Inc will post -1.05 EPS for the current year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics Inc (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply